Inappropriate continuation of stress ulcer prophylactic therapy after discharge

Annals of Pharmacotherapy

Volumn 41, Issue 10, 2007, Pages 1611-1616

  Wohlt, Paul D ^a,b   Hansen, Lizbeth A ^c,d   Fish, Jeffrey T ^a  

^a University of Wisconsin Health   (United States)

^b LDS HOSPITAL   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Critical care; Duodenal ulcer; Stress ulcer

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CRITICALLY ILL PATIENT; DIGESTIVE SYSTEM ULCER; DRUG COST; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STRESS ULCER; TREATMENT DURATION; TREATMENT INDICATION;

ADULT; AGED; ANTI-ULCER AGENTS; COHORT STUDIES; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT DISCHARGE; PEPTIC ULCER; RETROSPECTIVE STUDIES; STRESS; TIME FACTORS;

EID: 34748853031     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K227     Document Type: Article

References (25)

1. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients: resolving discordant meta-analyses. JAMA 1996;275:308-14.
2. American Society of Health-System Pharmacists Commission on Therapeutics. ASHP therapeutic guidelines on stress ulcer prophylaxis. Am J Health Syst Pharm 1999;56:347-79.
3. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. N Engl J Med 1998;338:791-7.
4. Cook D, Heyland D, Griffith L, et al. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Crit Care Med 1999;27:2812-7.
5. Mutlu GM, Mutlu EA, Factor P. GI complications in patients receiving mechanical ventilation. Chest 2001;119:1222-41.
6. Ben-Menachem T, McCarthy BD, Fogel R, et al. Prophylaxis for stress-related gastrointestinal hemorrhage: a cost-effectiveness analysis. Crit Care Med 1996;24:338-45.
7. Cook DJ, Fuller HD, Gordon HG, et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med 1994;330:377-81.
8. Gardner TB, Robertson DJ. Stress ulcer prophylaxis in non-critically ill patients: less may be more. Am J Gastroenterol 2006;101:2206-8.
9. Daley RJ, Rebuck JA, Welage LS, Rogers FB. Prevention of stress ulceration: current trends in critical care. Crit Care Med 2004;32:2008-13.
10. Goldin GF, Peura DA. Stress-related mucosal damage. What to do or not to do. Gastrointest Endosc Clin North Am 1996;6:505-26.
11. Wilcox CM, Spenney JG. Stress ulcer prophylaxis in medical patients: who, what, and how much? Am J Gastroenterol 1988;83:1199-211.
12. 2006 Redbook. 110th ed. Montvale, NJ: Thomson Healthcare, Inc., 2006.
13. Reusser P, Gyr K, Scheidegger D, et al. Prospective endoscopic study of stress erosions and ulcers in critically ill neurosurgical patients: current incidence and effect of acid-reducing prophylaxis. Crit Care Med 1990; 18:270-4.
14. Metz CA, Livingston DH, Smith JS, et al. Impact of multiple risk factors and ranitidine prophylaxis on the development of stress-related upper gastrointestinal bleeding: a prospective, multicenter, double-blind, randomized trial. Crit Care Med 1993;21:1844-9.
15. Klompmaker IJ, Slooff MJH, de Bruijn KM, et al. Prophylaxis with ranitidine against peptic ulcer disease after liver transplantation. Transpl Int 1988;1:209-12.
16. Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol 2006;107:2200-5.
17. Product information. Tagamet (cimetidine). Research Triangle Park, NC: GlaxoSmithKline, March 2005.
18. Product information. Protonix (pantoprazole). Philadelphia: Wyeth-Ayerst, April 2007.
19. Product information. Prilosec (omeprazole). Wilmington, DE: AstraZeneca, April 2007.
20. Product information. Prevacid (lansoprazole). Lake Forest, IL: TAP Pharmaceuticals, September 2006.
21. Product information. Zantac (ranitidine). Research Triangle Park, NC: GlaxoSmithKline, June 2007.
22. Product information. Pepcid (famotidine). Whitehouse Station, NJ: Merck & Co Inc., September 2004.
23. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955-60.
24. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294:2989-95.
25. Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis 2006;43:1272-6.